부산대학교 도서관

All patients experienced partial or full skin clearance within months of starting dupilumab in addition to patient-reported resolution of pruritus (Table 1). Dear Editor, Human immunodeficiency virus (HIV) infection is known to be associated with a wide spectrum of cutaneous manifestations that have continued to evolve in the era of highly active antiretroviral therapy (HAART).1,2 Patients living with HIV (PLWH) have increased risk of infectious, inflammatory, and neoplastic skin disorders,3 reflective of HIV-induced dysregulation of the immune system.4 Atopic dermatitis and disorders of pruritus have incidence as high as 37.5% in PLWH attributed to accentuated Th2 response in HIV.1 These disorders can be particularly challenging to treat, often refractory to multiple treatment modalities.1,5 Treatment may be further limited by provider hesitancy to use systemic immunomodulatory agents, given risk of further compromising the immune system in these patients. [Extracted from the article]